214 related articles for article (PubMed ID: 24987709)
1. HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas.
Rutten MJ; Dijk F; Savci-Heijink CD; Buist MR; Kenter GG; van de Vijver MJ; Jordanova ES
J Immunol Res; 2014; 2014():274584. PubMed ID: 24987709
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.
Babay W; Ben Yahia H; Boujelbene N; Zidi N; Laaribi AB; Kacem D; Ben Ghorbel R; Boudabous A; Ouzari HI; Rizzo R; Rebmann V; Mrad K; Zidi I
Hum Immunol; 2018 Jun; 79(6):463-470. PubMed ID: 29499226
[TBL] [Abstract][Full Text] [Related]
3. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Cancer Immunol Immunother; 2012 Aug; 61(8):1243-53. PubMed ID: 22258792
[TBL] [Abstract][Full Text] [Related]
7. High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma.
Ma Y; Ren Y; Zhang X; Lin L; Liu Y; Rong F; Wen W; Li F
Virchows Arch; 2014 Apr; 464(4):443-52. PubMed ID: 24458516
[TBL] [Abstract][Full Text] [Related]
8. HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer.
Schwich E; Rebmann V; Michita RT; Rohn H; Voncken JW; Horn PA; Kimmig R; Kasimir-Bauer S; Buderath P
Sci Rep; 2019 Apr; 9(1):5407. PubMed ID: 30932005
[TBL] [Abstract][Full Text] [Related]
9. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
10. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
Spentzos D; Levine DA; Ramoni MF; Joseph M; Gu X; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2004 Dec; 22(23):4700-10. PubMed ID: 15505275
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of high circulating sHLA-G in ovarian carcinoma.
Babay W; Boujelbene N; Ben Yahia H; Bortolotti D; Zemni I; Ouzari HI; Chelbi H; Mezlini A; Rizzo R; Zidi I
HLA; 2021 Oct; 98(4):357-365. PubMed ID: 34272932
[TBL] [Abstract][Full Text] [Related]
12. Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer.
Omichi C; Nakamura K; Haraga J; Masuyama H; Hiramatsu Y
Cancer Med; 2016 Jun; 5(6):1074-80. PubMed ID: 26929186
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
15. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
Vo D; Liu Y; Sood AK; Rezvani K; Jazaeri AA; Liu J
Cancer Biomark; 2024; 39(4):289-298. PubMed ID: 38250760
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.
Shehata M; Mukherjee A; Deen S; Al-Attar A; Durrant LG; Chan S
Br J Cancer; 2009 Oct; 101(8):1321-8. PubMed ID: 19755991
[TBL] [Abstract][Full Text] [Related]
17. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
18. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
19. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.
Wong RR; Chan LK; Tsang TP; Lee CW; Cheung TH; Yim SF; Siu NS; Lee SN; Yu MY; Chim SS; Wong YF; Chung TK
Gynecol Obstet Invest; 2011; 72(3):203-7. PubMed ID: 21860208
[TBL] [Abstract][Full Text] [Related]
20. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
